Bearish
Pfizer's stock price declines amid patent loss concerns and analyst downgrades.
Pfizer's stock has experienced a decline due to concerns over upcoming patent expirations and recent analyst downgrades. Barclays initiated coverage with an underweight rating, citing challenges from patent losses and balance sheet constraints. Additionally, Guggenheim reduced its price target to $35, maintaining a Buy rating, following a model update.
Key points
- Barclays initiates Pfizer stock with underweight rating on patent losses.
- Guggenheim cuts Pfizer stock price target to $35 on model update.
- Pfizer's stock price declines amid patent loss concerns and analyst downgrades.
Sources
AI-generated from public news sources. Not financial advice.
